Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | PRKACA | P17612 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CLK1 | P49759 | 1/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31396412 | 0.83 | POLB (0.56) | ROCK1MAPTLMNAPIK3CAPIK3CB | |
| SCHEMBL24175057 | 0.83 | POLB (0.56) | ROCK1MAPTLMNAPIK3CAPIK3CB | |
| SCHEMBL4706796 | 0.81 | PLK1 (0.61) | ROCK1HSP90AA1AURKAPRKACAADORA2A | |
| SCHEMBL2369694 | 0.80 | PIK3CA (0.57) | MAPTLMNAPIK3CAPIK3CBPIK3CG | |
| SCHEMBL27491688 | 0.77 | ASIC3 (0.56) | ROCK1MAPTLMNAPIK3CAPIK3CB | |
| SCHEMBL21164006 | 0.76 | HSP90AA1 (0.70) | ROCK1HSP90AA1AURKAPRKACAADORA2A | |
| SCHEMBL27609846 | 0.76 | ALDH1A1 (0.58) | ROCK1MAPTLMNAMEN1KMT2A | |
| SCHEMBL21373454 | 0.76 | PIK3CA (0.60) | MAPTLMNAPIK3CAPIK3CBPIK3CG | |
| SCHEMBL20265102 | 0.76 | CLK1 (0.60) | ROCK1PRKACAMAPTCLK1PIK3CA | |
| SCHEMBL18495641 | 0.76 | CLK1 (0.60) | ROCK1MAPTCLK1PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019134082-A1 | NOVEL PYRIMIDINE DERIVATIVES AS MTH1 INHIBITORS | WUXI ADVANT BIOTECHNOLOGY CO., LTD. (CN) | 2019-07-11 | — | — | WO | claimed |
| US-12208098-B2 | 4-carbonylamino-4-phenylpyrimidine compound or pharmaceutically acceptable salt thereof | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2025-01-28 | — | — | US | disclosed |
| US-20220000868-A1 | NOVEL 4-CARBONYLAMINO-4-PHENYLPYRIMIDINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2022-01-06 | — | — | US | disclosed |
| US-20220000868-A1 | NOVEL 4-CARBONYLAMINO-4-PHENYLPYRIMIDINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2022-01-06 | — | — | US | disclosed |
| WO-2020111283-A1 | NOVEL 4-CARBONYLAMINO-4-PHENYLPYRIMIDINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | (의료)길의료재단 | 2020-06-04 | — | — | WO | disclosed |
| WO-2019134082-A1 | NOVEL PYRIMIDINE DERIVATIVES AS MTH1 INHIBITORS | WUXI ADVANT BIOTECHNOLOGY CO., LTD. (CN) | 2019-07-11 | — | — | WO | disclosed |
| CN-104447706-A | 4-phenyl-2-aminopyrimidine compound, as well as preparation method and applications thereof | UNIV SHANDONG | 2015-03-25 | — | — | CN | disclosed |
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | BAYER SCHERING PHARMA AG (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1922306-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007026920-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000868-A1 | NOVEL 4-CARBONYLAMINO-4-PHENYLPYRIMIDINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | SLC5A1, DPP4, SLC10A1 | ROCK1 3393/4885HSP90AA1 2571/4885AURKA 4491/4885 |
| US-12208098-B2 | 4-carbonylamino-4-phenylpyrimidine compound or pharmaceutically acceptable salt thereof | SLC5A1, SLC10A1, DPP4 | ROCK1 3568/4885HSP90AA1 2661/4885AURKA 4378/4885 |
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | CDK2, MKI67, ERBB2 | ROCK1 2718/4885HSP90AA1 1462/4885AURKA 1541/4885 |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | ROCK1 1/4885HSP90AA1 1087/4885AURKA 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.